12:00 AM
 | 
Dec 21, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ridaforolimus: Completed Phase III enrollment

Ariad completed enrollment of 650 patients in the double-blind, placebo-controlled, international Phase III SUCCEED trial evaluating oral ridaforolimus. Merck and Ariad partnered to develop and commercialize ridaforolimus in 2007 (see BioCentury,...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >